Patent classifications
C12N2500/35
CELL CULTURE MEDIA
The present invention relates to dry cell culture media comprising amino acid components of certain particle size. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using amino acid components of certain particle sizes significantly reduces that problem.
Generating arterial endothelial cell populations
Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described. In particular, provided herein are efficient, defined, and scalable methods for generating human arterial endothelial cells from human pluripotent stem cells. Also provided herein are uses of human arterial endothelial cells obtained according to these methods. For example, methods of treating peripheral arterial disease and methods of screening agents for that effect adhesion of leukocytes to arterial endothelial cells are also provided.
COMPOSITIONS FOR USE AS A PROPHYLACTIC AGENT TO THOSE AT RISK OF INFECTION OF TUBERCULOSIS, OR AS SECONDARY AGENTS FOR TREATING INFECTED TUBERCULOSIS PATIENTS
The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype) (the MTB VAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
PROCESS FOR IMPROVING THE SOLUBILITY OF CELL CULTURE MEDIA
The invention relates to a process for improving the solubility of dry cell culture media. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using a stepwise procedure in which the amino acids present in the non-dissolving part are identified and added to a new batch in other particle sizes significantly reduces that problem.
METHODS OF PRODUCING POPULATIONS OF MESENCHYMAL STEM CELLS FROM PERIPHERAL BLOOD AND USES THEREOF
Disclosed herein are methods for providing a population of undifferentiated human mesenchymal stem cells (hMSCs). The methods include steps of, obtaining peripheral blood from a donor, adding glycerin to the peripheral blood, separating hMSCs from other somatic stem cells in the peripheral blood, and culturing the hMSCs in a medium containing glycerin thereby generating the population of undifferentiated hMSCs suitable for transplantation.
COMPOSITION FOR PROMOTING PRODUCTION OF STEM CELL-DERIVED EXOSOMES AND INCREASING STEMNESS
The present disclosure relates to a composition for promoting the production of stem cell-derived exosomes or increasing the stemness of stem cells. When the composition of the present disclosure is used in culturing stem cells, the stemness of stem cells and the yield of stem cell-derived exosomes are increased, and thus good-quality stem cells and stem cell-derived exosomes can be produced more efficiently, and accordingly, can be advantageously used in related research and development and commercialization.
Cell freezing medium for clinical use
Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na.sup.+, K.sup.+, Mg.sup.+, Cl.sup.−, and CH.sub.3COO.sup.− ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.
COMPOSITIONS AND METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS (HSCS)
The present disclosure provides methods for generating hematopoietic progenitor cells. In some embodiments, the methods involve an in vitro or ex vivo cell culture model utilizing retinoic acid signaling for producing hematopoietic progenitor cells from pluripotent stem cells.
Systems and methods for the production of diphtheria toxin polypeptides
An expression system and process for the production of Diphtheria toxin polypeptides or mutated forms thereof, such as the toxoid CRM197 polypeptide, in genetically-modified E. coli with high yield is described. The system and process is based on the uncoupling of biomass growth from recombinant protein induction, i.e. using an inducer of protein production that cannot be used as a carbon source for growth by the bacteria. The use of specific components and conditions that improve protein yields are also described.
COMPOSITIONS FOR USE AS A PROPHYLACTIC AGENT TO THOSE AT RISK OF INFECTION OF TUBERCULOSIS, OR AS SECONDARY AGENTS FOR TREATING INFECTED TUBERCULOSIS PATIENTS
The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.